AI주식인사이트AI Stock Insight
B

JW중외제약

001060KOSPI

67.7 / 100

Reference Date: 2026-09-08

Financial Score29.5 / 40
News Sentiment19.2 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Rose 9.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

JW Chungwa Pharmaceutical focuses on the research, development, manufacturing, and sales of pharmaceuticals, leveraging a strong pipeline of original drugs such as Rivaro and Winnerf, along with a global R&D network. The company offers a diverse range of specialty and over-the-counter medications, as well as healthcare products, maintaining a competitive edge in both domestic and international markets.

Number of Employees

1,106people

Average Salary

64.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
10.73Industry Average 15.006.5Point

Lower than industry avg (good)

PBR
1.71Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
17.60Industry Average 8.007.0Point

2.2x industry avg (excellent)

Debt Ratio
7.24Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼1.6% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 18.4% (improving, 3yr)

Detailed News Sentiment

54 totalPositive 44Neutral 10Negative 0Average Sentiment Score 76.7

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 27,200Won52-week high 39,05052-week low 20,950
1-month return5.0Point

1m +9.24% (rising)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0
  • Neutral투자판단관련주요경영사항2026-08-28
  • Neutral투자판단관련주요경영사항2026-08-14
  • Neutral반기보고서 (2026.06)2026-08-14
  • Neutral영업(잠정)실적(공정공시)2026-08-11
  • Neutral공정거래자율준수프로그램운영현황(안내공시)2026-08-11